Bibliographic information
GuidelineWHO recommendations on maternal health: guidelines approved by the WHO Guidelines Review Committee, second edition. Geneva: World Health Organization; 2025
Year of Publication2023
Issuing InstitutionWHO
Recommendation
Maintained
If intravenous oxytocin is unavailable, or if the bleeding does not respond to oxytocin, the use of intravenous ergometrine, oxytocin-ergometrine fixed dose, or a prostaglandin drug (including sublingual misoprostol, 800 µg) is recommended (for the treatment of postpartum haemorrhage)
Recommended in favor
Strong
Certainty of evidence
Low
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO recommendations for the prevention and treatment of postpartum haemorrhage
Year2012
InstitutionWorld Health Organization
Guideline
Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage
Year2025
InstitutionWorld Health Organization